Shares of Amicus Therapeutics (FOLD) have gained 12.9% over the past four weeks to close the last trading session at $6.83, ...

Amicus Therapeutics (FOLD) could be a solid choice for investors given the company's remarkably improving earnings outlook.

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

As you might know, Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) just kicked off its latest second-quarter results ...

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...

Amicus Therapeutics Inc (FOLD) reports its 17th consecutive quarter of double-digit revenue growth, while navigating increased operating expenses and ongoing litigation challenges.

Amicus Therapeutics (NASDAQ:FOLD) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

Amicus Therapeutics reported a remarkable 2024 with total revenue reaching approximately $528.5 million, reflecting a 32% year-over-year growth, driven mainly by strong demand for its products ...

For the quarter, Amicus generated $2.1 million in product revenue, which is up from zilch last year, when it had no products on pharmacy shelves, and a net loss of $46.7 million, or $0.33 per ...

Amicus Therapeutics will host a conference call and audio webcast today, November 6, 2024, at 8:30 a.m. ET to discuss the third quarter 2024 financial results and corporate updates.

Amicus' main drug is migalastat HCL, and is sold under the branded name Galafold. This drug was approved for commercialization in the EU in May of last year as treatment for a condition known as ...